Disc Medicine, Inc.
IRONUnited States
25 filed reports · 416 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
25 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 18 | 2,210 | Sep 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 1,776 | Dec 2020 to Dec 2025 |
| Current · 8-KSEC EDGAR | 1 | 1 | Jun 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 30, 2026 | 275 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 30, 2026 | 1 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 160 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 662 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 194 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 105 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 107 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 27, 2025 | 208 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 141 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 124 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 122 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 21, 2024 | 293 | Open |
Financial data
416 concepts · 3,987 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial408 concepts · 3,853 facts · Feb 2019 to Jul 2026
- Net income loss33 · Mar 2020 to Jun 2026
- Operating income loss33 · Mar 2020 to Jun 2026
- Allocated share based compensation expense32 · Mar 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents32 · Mar 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect32 · Mar 2020 to Jun 2026
- Increase decrease in accounts payable32 · Mar 2020 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets32 · Mar 2020 to Jun 2026
- Net cash provided by used in financing activities32 · Mar 2020 to Jun 2026
- Net cash provided by used in operating activities32 · Mar 2020 to Jun 2026
- Operating expenses (US GAAP)32 · Mar 2020 to Jun 2026
- Proceeds from stock options exercised32 · Mar 2020 to Jun 2026
- Research and development expense32 · Mar 2020 to Jun 2026
- Share based compensation32 · Mar 2020 to Jun 2026
- Stock granted during period value sharebased compensation32 · Mar 2020 to Jun 2026
- Stockholders equity (US GAAP)32 · Mar 2020 to Jun 2026
- Stock issued during period value stock options exercised32 · Mar 2020 to Jun 2026
- Preferred stock par or stated value per share31 · Sep 2020 to Jun 2026
- Preferred stock shares authorized31 · Sep 2020 to Jun 2026
- Accounts payable current30 · Sep 2020 to Jun 2026
- Additional paid in capital30 · Sep 2020 to Jun 2026
- Assets30 · Sep 2020 to Jun 2026
- Assets current30 · Sep 2020 to Jun 2026
- Cash and cash equivalents at carrying value30 · Sep 2020 to Jun 2026
- Common stock shares outstanding30 · Dec 2020 to Jun 2026
Segment7 concepts · 133 facts · Dec 2023 to Jun 2026
- Research and development expense66 · Dec 2023 to Jun 2026
- Allocated share based compensation expense13 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Segment reporting other item amount13 · Dec 2023 to Jun 2026
- Significant Segment Expense Category13 · Dec 2023 to Jun 2026
- Selling general and administrative expense2 · Dec 2023 to Dec 2024
KPI1 concepts · 1 facts · Jun 2026
- Clinical Trial Participants1 · Jun 2026
Segments
133 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments3 members · 133 facts
- Significant Segment Expense Category107 · Dec 2023 to Jun 2026
- Key Measure Of Segment Profit Or Loss13 · Dec 2023 to Jun 2026
- Other Segment Items13 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.